[Liraglutide reduces biomarkers and vascular risk in patients with diabetes mellitus type 2]

Rev Med Chil. 2013 Dec;141(12):1602-4. doi: 10.4067/S0034-98872013001200017.
[Article in Spanish]
No abstract available

Publication types

  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers / metabolism
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / metabolism
  • Female
  • Glucagon-Like Peptide 1 / analogs & derivatives*
  • Glucagon-Like Peptide 1 / therapeutic use
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Liraglutide
  • Male
  • Middle Aged
  • Risk Assessment
  • Young Adult

Substances

  • Biomarkers
  • Hypoglycemic Agents
  • Liraglutide
  • Glucagon-Like Peptide 1